Drug-maker Glenmark said that its specialty drugs and generics businesses performed well in the year ended March 2013.
“The US, India and Russia businesses continued to maintain its high growth trajectory,” said Glenn Saldanha, Chairman and Managing Director.
The company also made some progress on its research front with five new chemical entities and new biological entities getting into clinical trials, including Crofelemer which recently received approval from the US Food and Drug Administration for HIV associated diarrhoea, he added.
In the three months ended March 31, 2013, the company's revenues from the generics business was Rs 586 crore against Rs 468 crore in the corresponding period the previous year, a growth of 25 per cent. The specialty medicines business excluding out-licensing revenue was at Rs 741 crore against Rs 594 crore for the corresponding previous quarter, recording a growth of 24 per cent, the company said.
Cipla, one of India’s leading pharmaceutical companies, is delighted to announce the appointment of Mr. Subhanu Saxena as its Chief Executive Officer. Subhanu comes to Cipla with rich work experience of 25+ years, having worked with companies such as Citicorp, The Boston Consulting Group, and PepsiCo, across markets in Europe, North America, Africa and Asia.
In his last assignment he led the Global Product Strategy and Commercialization functions at Novartis Pharma AG. In this role, Subhanu was a part of the Global Pharma Executive Committee (USD 30 bn sales), with responsibility for marketing, sales, global medical affairs and health economics.
Osaka, Japan, and Bangalore, India, October 3, 2012 – Takeda Pharmaceutical Company Limited (Takeda) and Advinus Therapeutics Ltd. (Advinus) jointly announced today that they have entered into an agreement to initiate a three-year discovery collaboration focused on novel targets for major therapeutic areas, including Inflammation, CNS, and Metabolic diseases. In this collaboration, Advinus is responsible for leading the programs to create optimal IND ready compounds for pre-defined targets.